Eli Lilly And Co vs Invesco S&P 500 Low Volatility ETF — how do they compare? Eli Lilly And Co trades at $1,140.26 (market cap $1.02T), while Invesco S&P 500 Low Volatility ETF trades at $75.99. The key difference: Eli Lilly And Co pays a 0.6% dividend while Invesco S&P 500 Low Volatility ETF pays none. Which is the better fit depends on your goals.
| LLY | SPLV | |
|---|---|---|
Market Cap | $1.02T | — |
Sector | Health | — |
52-Week High | $1.24K | $77.45 |
52-Week Low | $625.65 | $70.30 |
Enterprise Value | $1.06T | — |
Dividend Yield | 0.6% | — |
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.
Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.
SPLV trades at $76.09, down 0.63% today, with a bullish technical outlook supported by moving averages and key support at $76. The ETF focuses on low-volatility S&P 500 stocks, offering stability amid market uncertainty, with recent news highlighting its defensive appeal during tech sell-offs and geopolitical tensions. Dividend distributions are scheduled for mid-2026 at $0.14 per share.
Outlook remains positive for risk-averse investors seeking equity exposure with reduced volatility, though reliance on market sentiment and interest rate trends poses risks. The ETF's strategy aligns with current defensive positioning, but limited growth potential may cap upside compared to broader market indices.
Trailing returns across standard periods
Latest headlines on both assets
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the "index Provider") compiles, maintains and calculates the underlying index, which is designed to measure the performance of the 100 least volatile constituents of the S&P 500 ® Index over the past 12 months as determined by the index Provider.
Read more on SPLV →